Novel findings for the development of drug therapy for various liver diseases: Liver microsomal triglyceride transfer protein activator may be a possible therapeutic agent in non-alcoholic steatohepatitis

Journal of Pharmacological Sciences

Volumn 115, Issue 3, 2011, Pages 270-273

  Fujita, Koji ^a   Imajo, Kento ^a   Shinohara, Yoshiyasu ^a   Nozaki, Yuichi ^a   Wada, Koichiro ^b   Yoneda, Masato ^a   Endo, Hiroki ^a   Takahashi, Hirokazu ^a   Abe, Yasunobu ^a   Inamori, Masahiko ^a   Shimamura, Takeshi ^a   Kobayashi, Noritoshi ^a   Kirikoshi, Hiroyuki ^a   Kubota, Kensuke ^a   Saito, Satoru ^a   Nakajima, Atsushi ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Liver disease; Microsomal triglyceride transfer protein (MTP); Non alcoholic fatty liver (NAFL); Non alcoholic steatohepatitis (NASH); Potential drug target; Very low density lipoprotein (VLDL) synthesis

Indexed keywords

APOLIPOPROTEIN B; GUANINE; MESSENGER RNA; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; THYMINE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ENZYME ACTIVITY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; INCIDENCE; LIPID LIVER LEVEL; LIPID METABOLISM; LIPOPROTEIN SYNTHESIS; LIVER CELL; LIVER DISEASE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SECRETION; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 79952788652     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.10R14FM     Document Type: Short Survey

References (27)

1. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis. 2008;28:339-350.
2. Farrell GC. Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region? J Gastroenterol Hepatol. 2003;18:124-138.
3. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221-1231.
4. James FW, Day CP. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol. 1998;29:495-501. (Pubitemid 28396672)
5. Matthews DR, Hosker JP, Rudenski AS. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetalogia. 1985;28:412-419. (Pubitemid 15018832)
6. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917-923. (Pubitemid 36397405)
7. Deng XQ, Chen LL, Li NX. The expression of SIRT1 in nonalcoholic fatty liver disease induced by high-fat diet in rats. Liver Int. 2007;27:708-715.
8. Kawaguchi K, Sakaida I, Tsuchiya M, Omori K, Takami T, Okita K, et al. Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. Biochem Biophys Res Commun. 2004;27:187-195. (Pubitemid 38175204)
9. Fujita K, Nozaki Y, Yoneda M, Wada K, Saito S, Nakajima A, et al. Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease. Gut. 2008;57:1583-1591.
10. Fujita K, Nozaki Y, Wada K, Yoneda M, Saito S, Nakajima A, et al. Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis. Hepatology. 2009;50:772-780.
11. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115:1343-1351. (Pubitemid 40629054)
12. Lee RG, Shah R, Sawyer JK, Hamilton RL, Parks JS, Rudel LL, et al. ACAT2 contributes cholesteryl esters to newly secreted VLDL, whereas LCAT adds cholesteryl ester to LDL in mice. J Lipid Res. 2005;46:1205-1212. (Pubitemid 43109835)
13. Havel RJ. Lipoproteins and lipid transport. Adv Exp Med Biol. 1975;63:37-59.
14. Hermier D, Salichon MR, Guy G, Peresson R. Differential channeling of liver lipids in relation to susceptibility to hepatic steatosis in the goose. Poultry Science. 1999;78:1398-1406. (Pubitemid 129555747)
15. Wetterau JR, Lin MC, Jamil H. Microsomal triglyceride transfer protein. Biochim Biophys Acta. 1997;1345:136-150. (Pubitemid 27138415)
16. Partin JS, Partin JC, Schubert WK, McAdams AJ. Liver ultrastructure in abetalipoproteinemia: evolution of micronodular cirrhosis. Gastroenterology. 1974;67:107-118.
17. Au WS, Kung HF, Lin MC. Regulation of microsomal triglyceride transfer protein gene by insulin in HepG2 cells. Roles of MAPK/erk and MAPK/p38. Diabetes. 2003;52:1073-1080.
18. Karpe F, Lundahl B, Ehrenborg E, Eriksson P, Hamsten A. A common functional polymorphism in the promoter region of the microsomal triglyceride transfer protein gene influences plasma LDL levels. Arterioscler Thromb Vasc Biol. 1998;18:756-761. (Pubitemid 28267655)
19. Bernard S, Touzet S, Personne I, Lapras V, Bondon PJ, Berthezene F, et al. Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with type II diabetes. Diabetologia. 2000;43:995-999. (Pubitemid 30655718)
20. Gambino R, Cassader M, Pagano G, Durazzo M, Musso G. Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH. Hepatology. 2007;45:1097-1107. (Pubitemid 46775771)
21. Raabe M, Véniant MM, Sullivan MA, Zlot CH, Björkegren J, Nielsen LB, et al. Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice. J Clin Invest. 1999;103:1287-1298. (Pubitemid 29218299)
22. Xie Y, Newberry EP, Young SG, Robine S, Hamilton RL, Wong JS, et al. Compensatory increase in hepatic lipogenesis in mice with conditional intestine-specific Mttp deficiency. J Biol Chem. 2006;281:4075-4086. (Pubitemid 43847833)
23. Lettéron P, Sutton A, Mansouri A, Fromenty B, Pessayre D. Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology. 2003;38:133-140. (Pubitemid 36775804)
24. Namikawa C, Shu-Ping Z, Vyselaar JR, Nozaki Y, Nemoto Y, Ono M, et al. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in nonalcoholic steatohepatitis. J Hepatol. 2004;40:781-786. (Pubitemid 38507358)
25. McPherson S, Jonsson JR, Barrie HD, O'Rourke P, Clouston AD, Powell EE. Investigation of the role of SREBP-1c in the pathogenesis of HCV-related steatosis. J Hepatol. 2008;49:1046-1054.
26. Mirandola S, Realdon S, Iqbal J, Gerotto M, Dal Pero F, Bortoletto G, et al. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology. 2006;130:1661-1669. (Pubitemid 43668848)
27. Fujita K, Yoneda M, Wada K, Saito S, Terauchi Y, Nakajima A, et al. Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats. Dig Dis Sci. 2007;52:3455-3464. (Pubitemid 350077187)